Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 15% Improvement Relative Risk HCQ for COVID-19  Cortez et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 280 patients in Philippines (March - October 2020) Study underpowered to detect differences Cortez et al., Western Pacific Surveil.., Nov 2021 Favors HCQ Favors control

Clinical characteristics and outcomes of COVID-19 patients in a tertiary hospital in Baguio City, Philippines

Cortez et al., Western Pacific Surveillance and Response Journal, doi:10.5365/wpsar.2021.12.4.852
Nov 2021  
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
Retrospective 280 hospitalized patients in the Philippines, 25 treated with HCQ, not showing any significant differences in unadjusted results.
Although the 15% lower mortality is not statistically significant, it is consistent with the significant 25% lower mortality [20‑29%] from meta analysis of the 250 mortality results to date.
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 15.0% lower, RR 0.85, p = 1.00, treatment 1 of 25 (4.0%), control 12 of 255 (4.7%), NNT 142.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cortez et al., 11 Nov 2021, retrospective, Philippines, peer-reviewed, 29 authors, study period March 2020 - October 2020.
This PaperHCQAll
Clinical characteristics and outcomes of COVID-19 patients in a tertiary hospital in Baguio City, Philippines
Karen Joyce Cortez, Bernard A Demot, Samantha S Bartolo, Dexter D Feliciano, Verna Moila Ciriaco, Imari Irish Labi, Denzelle Diane Viray, Jenna Charise Casuga, Karol Anne Camonayan-Flor, Precious Mae Gomez, Marie Ellaine Velasquez, Thea Pamela Cajulao, Jovy E Nigos, Maria Lowella De Leon, Domingo P Solimen, Angelita G Go, Francis M Pizarro, Larry C Haya Jr, Ray P Aswat, Virginia B Mangati, Caesar Noel Palaganas, Mylene N Genuino, Kimberley M Cutiyog-Ubando, Karen C Tadeo, Marinelle Longid, Nowell Benedict Catbagan, Joel B Bongotan, Beverly Anne Dominguez-Villar, Joeffrey B Dalao
Western Pacific Surveillance and Response Journal, doi:10.5365/wpsar.2021.12.4.852
oronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), primarily targets the respiratory system. In December 2019, an epidemiological alert was released in China following a rise in cases of pneumonia of unknown cause. The Philippines announced its first confirmed case on 31 January 2020. 1,2 The World Health Organization (WHO) officially declared a global pandemic on 11 March 2020, by which time the Philippines already had 49 confirmed cases, largely in the National Capital Region. 2 Baguio City is located north of Manila, within the Cordillera Central mountain range in northern Luzon. The estimated population is 345 000, with adults (aged 19-60 years) and those aged over 60 years comprising 52% and 6.6% of the population, respectively. 3 Leading causes of morbidity include hypertension, diabetes, bronchitis and asthma. 4 The first confirmed case in Baguio City was recorded on the city's ninth day of quarantine during March 2020, with local sustained transmission declared six months later. 5 Worldwide, by the end of October 2020, there were 43 623 111 confirmed cases and 1 161 311 deaths. At that time in the Philippines, cases had risen
Conflicts of interest The authors declare no conflicts of interest. Ethics approval This study has been approved by the Ethics Review Board of Baguio General Hospital and Medical Center, Baguio City, Philippines.
Adapa, Chenna, Balla, Merugu, Koduri et al., COVID-19 pandemic causing acute kidney injury and impact on patients with chronic kidney disease and renal transplantation, J Clin Med Res, doi:10.14740/jocmr4200pmid:32587651
Catajan, COVID-19 clusters in Baguio
Council, Eracoda, Group, Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA, Nephrol Dial Transplant, doi:10.1093/ndt/gfaa314pmid:33340043
Franceschi, Bonafè, Centenarians as a model for healthy aging, Biochem Soc Trans, doi:10.1042/bst0310457pmid:12653662
Ginsburg, Klugman, COVID-19 pneumonia and the appropriate use of antibiotics, Lancet Glob Health, doi:10.1016/s2214-109x(20)30444-7pmid:33188730
Henry, Aggarwal, Wong, Benoit, Vikse et al., Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: a pooled analysis, Am J Emerg Med, doi:10.1016/j.ajem.2020.05.073pmid:32738466
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1016/S0140-6736(20)30183-5pmid:31986264
Kolhe, Fluck, Selby, Taal, Acute kidney injury associated with COVID-19: a retrospective cohort study, PLoS Med, doi:10.1371/journal.pmed.1003406pmid:33125416
Liu, Zhang, He, Hematological findings in coronavirus disease 2019: indications of progression of disease, Ann Hematol, doi:10.1007/s00277-020-04103-5pmid:32495027
Long, Nie, Xiang, Li, Zhang et al., D-Dimer and prothrombin time are the significant indicators of severe COVID-19 and poor prognosis, BioMed Res Int, doi:10.1155/2020/6159720pmid:32596339
Marcon, Tettamanti, Capacci, Fontanel, Spanò et al., COVID-19 mortality in Lombardy: the vulnerability of the oldest old and the resilience of male centenarians, Aging (Albany NY), doi:10.18632/aging.103872pmid:32788424
Mesas, Cavero-Redondo, Álvarez-Bueno, Cabrera, De Andrade et al., Predictors of inhospital COVID-19 mortality: a comprehensive systematic review and meta-analysis exploring differences by age, sex and health conditions, PLoS One, doi:10.1371/journal.pone.0241742pmid:33141836
Mudatsir, Fajar, Wulandari, Soegiarto, Ilmawan et al., Predictors of COVID-19 severity: a systematic review and meta-analysis, doi:10.12688/f1000research.26186.1pmid:33163160
Peckham, De Gruijter, Raine, Radziszewska, Ciurtin et al., Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission, Nat Commun, doi:10.1038/s41467-020-19741-6pmid:33298944
Phoswa, Khaliq, Is pregnancy a risk factor of COVID-19?, Eur J Obstet Gynecol Reprod Biol, doi:10.1016/j.ejogrb.2020.06.058pmid:32620513
Sanyaolu, Okorie, Marinkovic, Patidar, Younis et al., Comorbidity and its impact on patients with COVID-19, SN Compr Clin Med, doi:10.1007/s42399-020-00363-4pmid:32838147
Simadibrata, Calvin, Wijaya, Ibrahim, Neutrophil-to-lymphocyte ratio on admission to predict the severity and mortality of COVID-19 patients: A meta-analysis, Am J Emerg Med, doi:10.1016/j.ajem.2021.01.006pmid:33453617
Singer, Deutschman, Seymour, Shankar-Hari, Annane et al., The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3), JAMA, doi:10.1001/jama.2016.0287pmid:26903338
Soria, Macalalad-Josue, Quiwa, Duya, Calvario et al., Clinical profile and outcomes of hospitalized patients with COVID-19 in the Philippines: a preliminary report
Talavera, García-Azorín, Martínez-Pías, Trigo, Hernández-Pérez et al., Anosmia is associated with lower in-hospital mortality in COVID-19, J Neurol Sci, doi:10.1016/j.jns.2020.117163pmid:33035870
Wang, He, Yu, Hu, Jiang, Prolonged prothrombin time at admission predicts poor clinical outcome in COVID-19 patients, World J Clin Cases, doi:10.12998/wjcc.v8.i19.4370pmid:33083396
Williamson, Walker, Bhaskaran, Bacon, Bates et al., Factors associated with COVID-19-related death using OpenSAFELY, Nature, doi:10.1038/s41586-020-2521-4pmid:32640463
Xu, Liang, Shi, Zhang, Wang, A meta-analysis on the risk factors adjusted association between cardiovascular disease and COVID-19 severity, BMC Public Health, doi:10.1186/s12889-021-11051-wpmid:34380456
Yan, Faraji, Prajapati, Ostrander, Deconde, Selfreported olfactory loss associates with outpatient clinical course in COVID-19, Int Forum Allergy Rhinol, doi:10.1002/alr.22592pmid:32329222
Zahra, Iddawela, Pillai, Choudhury, Harky, Can symptoms of anosmia and dysgeusia be diagnostic for COVID-19?, Brain Behav, doi:10.1002/brb3.1839pmid:32935915
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566pmid:32171076
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop